Evolus (EOLS) has a profit margin of -14.39%, below the Healthcare sector average of 15.29%.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
Evolus (EOLS) currently reports a profit margin of -14.39% as of March 2026. That compares with -20.51% in the prior-year period — up 29.8% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Evolus's profit margin history and peer comparisons.
Evolus's profit margin increased from -20.51% to -14.39% — a 29.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Evolus's profit margin of -14.39% is lower than the Healthcare sector average of 15.29%. That is roughly 194.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Evolus's current -14.39% should be judged against Healthcare norms (sector average: 15.29%) and against EOLS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -14.39%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Evolus, and consider following EOLS for alerts when major investors trade the stock.